Is cimepilimab on the market?

Cemiplimab (Cemiplimab) is a fully human monoclonal antibody that targets programmed death receptor-1 (PD-1), which acts as a negative regulator of T cell function. By blocking PD-1, cemiplimab can enhance T cell-mediated anti-tumor responses. The drug was approved by the U.S. Food and Drug Administration (FDA) on September 28, 2018, becoming the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC). Since then, cimepilimab has also been approved for indications in basal cell carcinoma (BCC) and non-small cell lung cancer (NSCLC). Cimepilimab was also approved by the European Commission on June 28, 2019, with the trade name Libtayo.

The approval of cimepilimab brings new hope for the treatment of cutaneous squamous cell carcinoma, a cancer that has few effective treatment options after it spreads. At the same time, there was a lack of other second-line treatment options for basal cell carcinoma when it was approved. This makes cimepilimab particularly important in clinical applications. In addition, the drug has shown promising efficacy in the treatment of non-small cell lung cancer patients with high PD-L1 expression, as well as cervical cancer that has progressed during or after platinum-based chemotherapy. Especially when used in combination with platinum-based chemotherapy, cimepilimab has a significant therapeutic effect on non-small cell lung cancer, provided that at least 1% of the tumor cells have positive PD-L1 expression.

Regarding the safety of cimepilimab, clinical studies have shown that its side effects are relatively controllable and similar to those seen in other monoclonal antibody treatments. Common side effects include fatigue, rash, and abnormal liver function, but in most cases these side effects can be managed and do not have a significant impact on the patient's overall treatment.

Reference materials:https://go.drugbank.com/drugs/DB14707